IOL Chemicals & Pharmaceuticals Ltd Q3 FY26 Earnings Analysis

Published 4 Aug 2026 | Pharmaceuticals & Biotechnology | Market Cap: ₹2.8K Cr

Price

152

Market Cap

₹2.8K Cr

P/E Ratio

22.2

Earnings Summary

No information is provided regarding the same in the latest conference call. No information is provided regarding the same in the latest conference call.

📊 Revenue & Sales Performance

No information is provided regarding the same in the latest conference call.

📈 Profitability & Margins

No information is provided regarding the same in the latest conference call.

🏗️ Capital Expenditure Plans

No information is provided regarding the same in the latest conference call.

💰 Fundraising & Capital Structure

No information is provided regarding the same in the latest conference call.

📋 Order Book & Pipeline

No information is provided regarding the same in the latest conference call.

Key Metrics

Frequently Asked Questions

What were IOL Chemicals & Pharmaceuticals Ltd Q3 FY26 results?

No information is provided regarding the same in the latest conference call. No information is provided regarding the same in the latest conference call.

What is IOL Chemicals & Pharmaceuticals Ltd share price analysis?

IOL Chemicals & Pharmaceuticals Ltd currently shows a neutral. The stock trades at a P/E of 22.2 with a market cap of ₹2,769. Investors should review the full earnings analysis for detailed insights.

Is IOL Chemicals & Pharmaceuticals Ltd planning capital expenditure?

No information is provided regarding the same in the latest conference call.

This analysis is AI-generated based on publicly available earnings data and concall transcripts. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.

Others in Pharmaceuticals & Biotechnology this season

  • Strides Pharma Science Ltd (Q3 FY26)

    Strides Pharma Science Ltd Q3 FY26 quarterly results analysis. No information is provided regarding the same in the latest conference call. Market Cap ₹10,634,

  • Shilpa Medicare Ltd (Q3 FY26)

    Shilpa Medicare Ltd Q3 FY26 quarterly results analysis. No information is provided regarding the same in the latest conference call. Market Cap ₹9,357, P/E 52.9

  • Orchid Pharma Ltd (Q3 FY26)

    Orchid Pharma Ltd Q3 FY26 quarterly results analysis. - Financial year 2026 expected to remain muted operationally with no signs of market recovery in the curre

  • Divis Laboratories Ltd (Q3 FY26)

    Divis Laboratories Ltd Q3 FY26 quarterly results analysis. - The company has a healthy project pipeline, with multiple projects at different milestones; outcome